Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

InMed Pharmaceuticals (INM) Accumulated Depreciation & Amortization (2020 - 2025)

InMed Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $1.3 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization fell 1.25% year-over-year to $1.3 million; the TTM value through Jun 2025 reached $1.3 million, down 1.25%, while the annual FY2025 figure was $1.3 million, 1.25% down from the prior year.
  • Accumulated Depreciation & Amortization for Q2 2025 was $1.3 million at InMed Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $1.4 million in Q2 2024 and troughed at -$1.4 million in Q4 2023.
  • A 5-year average of $688375.6 and a median of $819320.0 in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 300.99% in 2023 and later skyrocketed 179.14% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $320520.0 in 2021, then surged by 123.64% to $716800.0 in 2022, then tumbled by 300.99% to -$1.4 million in 2023, then skyrocketed by 179.14% to $1.1 million in 2024, then grew by 17.38% to $1.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for INM at $1.3 million in Q2 2025, $1.2 million in Q1 2025, and $1.1 million in Q4 2024.